Compared to placebo, treatment with ustekinumab resulted in a significantly greater proportion of adults with moderate to severe UC achieving clinical remission at week 44 (primary endpoint).
Guidelines address diagnosis, treatment, and overall clinical management of adult patients
This article is part of MPR‘s coverage of the American Academy of Allergy, Asthma & Immunology annual meeting, taking place in San Francisco, California. Our staff will report on medical research related to asthma, allergy, and other respiratory conditions, conducted by experts in the field. Check back regularly for more news from AAAAI 2019. SAN FRANCISCO — Patients…
The FDA has approved the supplemental New Drug Application sNDA for Cinvanti (aprepitant) to expand administration to include a 2-minute intravenous injection, in addition to the already approved 30-minute IV infusion.
People who take gastric acid suppression agents have a high risk of requiring subsequent anti-allergy drugs.
Results of a recently published trial suggested pregabalin, a calcium channel alpha-2 delta ligand, may reduce gastrointestinal symptoms of irritable bowel syndrome.
Nexus announced that the Food and Drug Administration (FDA) has approved Dicyclomine HCl Injection, 20mg/2mL, the generic version of Aptalis Pharma’s Bentyl Injection.
The ERADICATE Hp2 trial enrolled 455 dyspepsia patients at 55 sites across the US and randomized them to receive 4 capsules, 3 times daily, of either Talicia or the active comparator (amoxicillin 250mg and omeprazole 10mg), for a period of 14 days.
A total of 354 participants were randomly assigned to individual hypnotherapy, group hypnotherapy, and educational supportive therapy; after excluding ineligible participants, 142, 146, and 54 participants, respectively.
The Company has completed a first in human study in healthy volunteers; a Phase 2 trial in adults with NASH is due to begin soon in the US.
